ClinicalTrials.gov
ClinicalTrials.gov Menu

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00063817
Recruitment Status : Completed
First Posted : July 8, 2003
Last Update Posted : December 27, 2017
Sponsor:
Collaborator:
Immune Tolerance Network (ITN)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a relative with the same (or nearly the same) blood cell type as the transplant recipient. An investigational medication will be given prior to and after the transplant to help protect the transplanted kidney from attack by the body's immune system.

Condition or disease Intervention/treatment Phase
End-stage Renal Disease Renal Transplantation Kidney Transplantation Drug: Conditioning Regimen Phase 1

Detailed Description:

Of the two currently available treatments for kidney failure, long-term dialysis and kidney transplantation, only kidney transplantation provides a potential cure. After a kidney transplant, the body's immune system recognizes the kidney as foreign and tries to attack and destroy it in a process called rejection. To avoid rejection, participants must take medications called immunosuppressants or anti-rejection drugs. It is believed that by transplanting bone marrow at the same time as a solid organ such as a kidney, a state of "mixed chimerism" (a mixing of the donor and recipient's immune system) can be achieved. Mixed chimerism may prevent rejection without the need for anti-rejection drugs.

Participants in this study will receive a simultaneous bone marrow and kidney transplant from the same living related donor in an attempt to establish mixed chimerism. Prior to transplantation, participants will undergo a "conditioning regimen" involving cyclophosphamide chemotherapy, radiation to the thymus gland, and four immunosuppressive medications: cyclosporine A, a man-made antibody known as rituximab to suppress B cells, a short course of steroids, and a T-cell depleting antibody known as MEDI-507. MEDI-507 is an investigational medication that has not been approved by the FDA. The primary goal of the study is to investigate the safety of the conditioning regimen and its ability to promote mixed chimerism so that the transplanted kidney is not destroyed. The study will also determine whether participants with mixed chimerism can eventually be safely removed from long-term immunosuppressive therapy following transplantation.

Participants will be assessed before and after transplantation and will be followed ≤36 months.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)
Study Start Date : June 2003
Actual Primary Completion Date : January 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Conditioning Regimen

Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.

Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.

Drug: Conditioning Regimen
Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
Other Name: nonmyeloablative preparative regimen




Primary Outcome Measures :
  1. Graft Survival Twenty-Four Months Post Transplantation [ Time Frame: 24 months (2 Years) Post Transplantation ]
    Defined by kidney transplant survival at month 24 post transplantation with successful withdrawal of cyclosporine following transplantation, in the absence of maintenance immunosuppression.


Secondary Outcome Measures :
  1. Participant Survival [ Time Frame: Up to thirty-six months (3 Years) Post Transplantation ]
    During the three-year post-transplant follow-up period for enrolled participants.

  2. Graft Survival [ Time Frame: Up to thirty-six months (3 Years) Post Transplantation ]
    During the three-year post-transplant follow-up period for enrolled participants.

  3. Change from Baseline in Renal Function Using Serum Creatinine [ Time Frame: Up to thirty-six months (3 Years) Post Transplantation ]
    Changes in serum creatinine levels from baseline through post transplantation follow-up period.

  4. Number of Episodes of Acute or Chronic Graft Versus Host Disease (GVHD) [ Time Frame: From Week 1 through thirty-six months (3 Years) Post Transplantation ]
    Evaluations for suspected GVHD, including biopsies as appropriate, during routine and/or for cause assessments.

  5. Number of Adverse Events [ Time Frame: Participant enrollment through <=thirty-six months (3 Years) Post Transplantation ]
    As defined by protocol.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • End-stage renal disease (ESRD) without prior sensitization (defined as Panel Reactive Antibody [PRA] greater than 20%) within the 60 days prior to transplant as measured by cytotoxicity assays, ELISA, and flow cytometry;
  • Undergoing a first or second transplant;
  • Receiving a transplant from a living related donor who is ABO (blood type) compatible and haploidentical (3, 4, or 5 antigen match by serologic typing);
  • Cardiac ejection fraction greater than 40%;
  • Forced expiratory volume (FEV1) greater than 50%;
  • Liver function tests, bilirubin, and coagulation studies less than 2 X normal;
  • White blood cells greater than 2000/mm^3; abd
  • Platelets greater than 100,000/mm^3

Exclusion Criteria:

  • Positive donor lymphocyte cross-match;
  • HIV-1 infected;
  • Positive hepatitis B surface antigen (HbsAg);
  • Hepatitis C virus infected;
  • History of cancer;
  • Prior dose-limiting radiation therapy;
  • Pregnant, breastfeeding, or planning pregnancy within the time frame of the study;
  • Enrolled in another investigational drug study within 30 days prior to study entry; or
  • Receiving maintenance immunosuppression within 3 months before the conditioning regimen begins

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00063817


Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network (ITN)
Investigators
Principal Investigator: David H. Sachs, MD Department of Medicine, Massachusetts General Hospital
Principal Investigator: A. Benedict Cosimi, MD Department of Medicine, Massachusetts General Hospital

Additional Information:
Publications of Results:
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00063817     History of Changes
Other Study ID Numbers: DAIT ITN010ST
DAIT NKD03 ( Other Identifier: Immune Tolerance Network )
First Posted: July 8, 2003    Key Record Dates
Last Update Posted: December 27, 2017
Last Verified: December 2017

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
End-stage renal disease
Renal Transplant
Bone Marrow Transplant
nonmyeloablative conditioning regimen

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Cyclophosphamide
Cyclosporins
Cyclosporine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Enzyme Inhibitors
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Calcineurin Inhibitors